Purpose: To investigate the degree of arterial blood supply of portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC), and to evaluate its impact on overall survival after transarterial chemoembolization using lipiodol +/- gelatin sponge particles (TACE).

Results: Of the 10 patients who underwent surgery, the number of patients with good/mild/poor staining of PVTT by methylene blue were 3, 4, and 3, respectively. The degrees of methylene blue staining in these patients correlated well with the degrees of accumulation of lipiodol in PVTT in these patients, i.e. good/mild/poor in 3, 4, and 3 patients, respectively. For the 77 patients who underwent TACE as treatment, they were divided into 2 groups: good accumulation of lipiodol ( = 27) and mild/poor accumulation of lipiodol ( = 50) on CT. The overall median survival between the 2 groups was 10.0 months vs 2.7 months, ( < 0.001). Multi-variable analysis showed degree accumulation of Lipiodol (OR, 2.057; 95% CI,1.414-2.993; < 0.001) to be an independent prognostic factor.

Patients And Methods: Patients with HCC with PVTT who underwent surgical resection received preoperative TACE. At operation, arterial injection of methylene blue into the common hepatic artery was carried out. During the study period, other patients with unresectable HCC with PVTT were treated with TACE.

Conclusion: In about 1/3 of patients with HCC with PVTT, the arterial blood supply from the hepatic artery to the PVTT was good. These patients responded better to TACE than those patients with mild/poor arterial supply.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668096PMC
http://dx.doi.org/10.18632/oncotarget.19767DOI Listing

Publication Analysis

Top Keywords

accumulation lipiodol
16
patients
13
arterial blood
12
blood supply
12
methylene blue
12
hcc pvtt
12
supply portal
8
portal vein
8
vein tumor
8
tumor thrombus
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!